Alere (ALRPRB.PFD) Risk Assessment

View and export this data going back to 2008. Start your Free Trial

What is Alere Risk Assessment?

Risk Assessment represents the investment risk of a stock derived from our exclusive method. It suggests how risky the investment opportunity is based on the valuation and the fundamental performance of the stock. It is derived from following key aspects:

1. GuruFocus internally developed valuations of the stock, such as GF valuation.
2. Quality Rank, a business quality indicator developed by GuruFocus.
3. Fundamental performance: Piotroski F-Score, Altman Z-Score, Beneish M-Score, etc.
4. Growth opportunities: 5-year revenue growth rate, 5-Year EPS without NRI Growth Rate, etc.

Value investors are always willing to find undervalued stocks. However, not all the undervalued stocks are good deals, we should also be careful of how risky the investment opportunity is. We believe that if the company's financial strength and profitability are strong, and the stock price is within a reasonable range of the GF valuation, or stock has a high return with its price being undervalued, then it might be a good investment opportunity with low risk.

Based on those aspects listed above, GuruFocus believes the risk assessment of Alere is: No Data: Cannot be evaluated.

Competitive Comparison of Alere's Risk Assessment

For the Diagnostics & Research subindustry, Alere's Risk Assessment, along with its competitors' market caps and Risk Assessment data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Alere's Risk Assessment Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Alere's Risk Assessment distribution charts can be found below:

* The bar in red indicates where Alere's Risk Assessment falls into.

Alere (NYSE:ALRPRB.PFD) Risk Assessment Explanation

Based on the four aspects listed above, GuruFocus provides the following 7 evaluations:

All-in-One Screener Examples (1)
Low Risk: Strong fundamentals, worth long-term holding
Moderate Risk: Sensitive, better choose undervalued stock
High Risk: High uncertainty with risk-return tradeoff
High Risk: Good fundamentals, beware of shrinking business
High Risk: Sensitive to economic or industry trends
High Risk: High uncertainty
No Data: Cannot be evaluated

(1) These are some simple examples. You can access our Risk Assessment filter under All-in-One Screener’s Fundamental tab and set your own criteria.

Alere Risk Assessment Related Terms

Thank you for viewing the detailed overview of Alere's Risk Assessment provided by GuruFocus.com. Please click on the following links to see related term pages.

Alere (ALRPRB.PFD) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Alere Inc (NYSE:ALRPRB.PFD) » Definitions » Risk Assessment

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

http://www.alere.com

Alere, Inc. develops rapid point-of-care diagnostic devices in cardiology, infectious disease, toxicology, diabetes, oncology, and women's health. North America accounts for the largest portion of the firm's revenue (55%), followed by Europe (19%), Asia-Pacific (14%), and the rest of the world (12%). Alere's headquarters are in Waltham, Massachusetts.

Executives

John Bridgen	officer: Sr VP, Business Development	51 SAWYER ROAD, C/O INVERNESS MEDICAL INNOVATIONS INC, WALTHAM MA 02453
Geoffrey S Ginsburg	director	51 SAWYER ROAD, SUITE 200, WALTHAM MA 02453
Renuka Uppaluri	officer: Senior VP, Global R&D	51 SAWYER ROAD, SUITE 200, WALTHAM MA 02453
Mark Gladwell	officer: Senior VP, Global Operations	51 SAWYER ROAD, SUITE 200, WALTHAM MA 02453
Gregg J Powers	director	C/O QUANTUM CORPORATION, 224 AIRPORT PARKWAY SUITE 300, SAN JOSE CA 95110
Jonathan Wygant	officer: VP, Controller, CAO	3750 TORREY VIEW COURT, SAN DIEGO X1 92130
Thomas Mckillop	director	51 SAWYER ROAD, SUITE 200, WALTHAM MA 02453
Melissa Guerdan	officer: SVP, Global Quality & Reg.	51 SAWYER ROAD, SUITE 200, WALTHAM MA 02453
Daniella Cramp	officer: Global Pres., Cardiometabolic	51 SAWYER ROAD, SUITE 200, WALTHAM MA 02453
Sanjay Malkani	officer: Global Pres., Toxicology	51 SAWYER ROAD, SUITE 200, WALTHAM MA 02453
James Jr. Roosevelt	director	51 SAWYER ROAD, SUITE 200, HOPKINTON MA 02453
Robert Bernard Hargadon	officer: SVP, Global Human Resources	4327 LAKE WASHINGTON BLVD NE #6208, KIRKLAND WA 98033
John F Levy	director	C/O INNVERNESS MEDICAL INNOVATIONS, INC., 51 SAWYER ROAD, WALTHAM MA 02453
John Quelch	director	C/O INVERNESS MEDICAL INNOVATIONS INC, 51 SAWYER RD, WALTHAM MA 02453
Carol R Goldberg	director	C/O INVERNESS MEDICAL INNOVATIONS INC, 51 SAWYERS RD, WALTHAM MA 02453